Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)
06 Februar 2023 - 6:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant
☐ Filed by a party other than the Registrant ☒
Check the appropriate box:
☐ |
Preliminary Proxy Statement |
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2)) |
☐ |
Definitive Proxy Statement |
☒ |
Definitive Additional Materials |
☐ |
Soliciting Material under §240.14a-12 |
Opiant Pharmaceuticals, Inc.
(Name of Registrant as Specified In Its Charter)
Indivior PLC
(Name of
Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
|
|
|
|
|
☒ |
|
No fee required. |
|
|
☐ |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
|
|
|
|
(1) |
|
Title of each class of securities to which transaction applies:
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies:
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11
(set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction:
|
|
|
(5) |
|
Total fee paid:
|
|
|
☐ |
|
Fee paid previously with preliminary materials. |
|
|
☐ |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|
|
|
|
|
(1) |
|
Amount Previously Paid:
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.:
|
|
|
(3) |
|
Filing Party:
|
|
|
(4) |
|
Date Filed:
|
On February 6, 2023, Indivior PLC (Indivior) published a press release announcing the
expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, with respect to the proposed acquisition of Opiant Pharmaceuticals, Inc. by Indivior. Indivior files the press release herewith pursuant
to Rule 14a-12 under the Securities Exchange Act of 1934, as amended.
Indivior Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Opiant Pharmaceuticals, Inc.
Slough, UK, and Richmond, VA, February 6, 2023 - Indivior PLC (LSE: INDV) today
announces the expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), with respect to the previously announced agreement to acquire Opiant Pharmaceuticals,
Inc. (Opiant) for $20.00 per share in cash plus up to $8.00 per share in contingent value rights.
The expiration of the
HSR waiting period occurred at 11:59 p.m. EDT on February 2, 2023, which was a condition to the closing of the pending transaction. Completion of the transaction is subject to the satisfaction of the remaining customary closing
conditions, including approval by Opiant stockholders and the receipt of remaining applicable regulatory approvals.
About Indivior
Indivior is a global pharmaceutical company working to help change patients lives by developing medicines to treat substance use disorders (SUD) and
serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and
potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA,
Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Opiant Pharmaceuticals Inc (NASDAQ): 0 Nachrichtenartikel
Weitere Opiant Pharmaceuticals, Inc. News-Artikel